Skip to main content
    V

    Vivos Therapeutics Inc (VVOS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.13
    -0.01 (-5.37%)

    Market Cap: $4.50M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    30%(7/23)
    Avg Surprise
    -21.16%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.30
    Range$-0.54 - $-0.12
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.25-19.4%
    60d ago$-0.42+28.0%
    30d ago$-0.300.0%
    7d ago$-0.300.0%
    Current$-0.30
    Revenue Consensus
    $5M
    Range$5M - $5M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.99 - $0.40
    4 analysts
    Revenue Consensus
    $6M
    Range$6M - $6M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.30---
    Jun 26
    Reported Aug 14
    		$-0.31$-0.42+26.19%Beat+43.6%
    Mar 26
    Reported Apr 15
    		$-0.52$-0.45-15.56%Miss-15.6%
    Dec 25
    Reported Mar 26
    		$-0.58$-0.49-17.17%Miss-107.1%
    Sep 25
    Reported Nov 19
    		$-0.49$-0.51+3.92%Beat-22.5%
    Jun 25
    Reported Aug 19
    		$-0.55$-0.38-44.74%Miss+8.3%
    Mar 25
    Reported May 15
    		$-0.45$-0.44-2.27%Miss+72.4%
    Dec 24
    Reported Mar 31
    		$-0.28$-0.43+34.88%Beat+90.8%
    Sep 24
    Reported Nov 14
    		$-0.40$-0.70+42.86%Beat+87.0%
    Jun 24
    Reported Aug 14
    		$-0.60$-1.05+42.86%Beat+84.6%
    Mar 24
    Reported May 14
    		$-1.63$-1.16-40.52%Miss-209.4%
    Dec 23
    Reported Mar 28
    		$-3.05$-1.90-60.53%Miss-1425.0%
    Sep 23
    Reported Nov 14
    		$-3.08$-3.00-2.67%Miss+52.6%
    Jun 23
    Reported Aug 16
    		$-3.89$-3.50-11.14%Miss-1289.3%
    Mar 23
    Reported Jun 8
    		$1.49N/A+131.37%Beat+118.6%
    Dec 22
    Reported Mar 30
    		$-0.20$-0.22+9.09%Beat+41.2%
    Sep 22
    Reported Dec 20
    		$-6.50$-6.25-4.00%Miss+0.0%
    Jun 22
    Reported Aug 23
    		$-0.28$-0.25-12.00%Miss+94.1%
    Mar 22
    Reported May 16
    		$-8.01$-6.50-23.23%Miss-68.6%
    Dec 21
    Reported Mar 31
    		$-0.34$-0.25-36.00%Miss+61.4%
    Sep 21
    Reported Nov 15
    		$-6.50$-4.62-40.69%Miss-2726.1%
    Jun 21
    Reported Aug 12
    		$-4.75$-4.50-5.56%Miss-2803.4%
    Mar 21
    Reported May 17
    		$-4.75$-4.25-11.76%Miss-2549.2%
    Dec 20
    Reported Mar 25
    		$-0.88$-0.16-450.00%Miss-390.8%
    Sep 20
    Reported Dec 14
    		$-0.23$0.00N/AMiss+14.7%
    Jun 20
    Reported Sep 30
    		$-0.16$0.00N/AMiss+27.6%
    Mar 20
    Reported Jun 29
    		$-0.18$0.00N/AMiss+20.6%
    Dec 19
    Reported Mar 31
    		$-0.18$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-0.27$0.00N/AMiss-
    Mar 19
    Reported Jun 29
    		$-0.23$0.00N/AMiss-
    Dec 18
    Reported Mar 30
    		$-0.23$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.07EV/EBITDAN/A
    Price/FCF-0.10xFCF Yield-1028.29%
    Profitability
    Profit Margin-121.80%Operating Margin-93.60%
    ROE-8585.00%ROIC-459.49%
    Financial Health
    Debt/Equity-2.15xInterest CoverageN/A
    Current Ratio0.21xQuick Ratio0.21x
    Trading Statistics
    Beta6.07Avg Volume4.91M
    52-Week High$3.1052-Week Low$0.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.15
    SMA 20$0.15
    SMA 50$0.21
    SMA 200$0.87
    EMA 10$0.15
    EMA 20$0.16
    EMA 50$0.23
    EMA 200$0.88

    MACD

    Line: -0.02Signal: -0.02Hist: 0.00

    ADX

    ADX: 12.8+DI: 21.1-DI: 19.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down56.0
    PSAR$0.15

    Bollinger Bands

    Upper Band$0.17
    Lower Band$0.13
    %B Position2564%(Upper)
    Band Width0.08

    RSI (14-Day)

    Oversold
    29.5

    Momentum Oscillators

    Stoch %K35.0
    Stoch %D43.7
    Williams %R-83.5
    ROC (10d)-9.4%
    Momentum-0.01
    CCI (20d)-122.8
    MFI (14d)93.5

    Volatility Measures

    ATR (14d)$0.02(12.7%)
    StdDev (20d)0.01
    Hist Vol72.9%(High)

    Volume Flow

    VWAP$0.14
    OBV-441.8M
    AD Line-486.2M
    CMF (20d)0.416

    Volume Metrics

    Avg Vol (20d)5.3M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.15

    Pivot Points

    R3$0.16
    R2$0.15
    R1$0.15
    Pivot Point$0.14
    S1$0.14
    S2$0.13
    S3$0.13

    Advanced Oscillators

    TSI-34.34
    Ultimate Osc41.5
    KST-247.56

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.15M$5.14M$3.82M$6.78M$3.82M$3.02M$3.70M$3.86M$4.05M$3.42M$3.25M$3.30M
    Cost of Revenue$2.20M$2.08M$838,000$2.85M$1.71M$1.51M$1.60M$1.53M$1.40M$1.48M$1.16M$1.55M
    Gross Profit$2.95M$3.06M$2.99M$3.94M$2.11M$1.51M$2.10M$2.33M$2.65M$1.94M$2.09M$1.75M
    Operating Expenses$7.78M$9.67M$9.36M$8.67M$6.97M$5.43M$4.90M$4.98M$4.59M$5.72M$6.22M$5.39M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$7.11M$8.97M$8.54M$7.88M$6.41M$4.89M$4.35M$4.49M$4.12M$4.92M$5.47M$4.60M
    Operating Income$-4,825,000$-6,615,000$-6,377,000$-4,734,000$-4,865,000$-3,918,000$-2,805,000$-2,645,000$-1,936,000$-3,785,000$-4,134,000$-3,640,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$698,000$1.14M$576,000$666,000$148,000$0$22,000$0$0$0$125,000$0
    Income Before Tax$-5,523,000$-7,751,000$-6,953,000$-5,400,000$-5,013,000$-3,864,000$-2,827,000$-2,616,000$-1,930,000$-3,763,000$-4,259,000$-2,093,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,523,000$-7,751,000$-6,953,000$-5,400,000$-5,013,000$-3,864,000$-2,827,000$-2,616,000$-1,930,000$-3,763,000$-4,259,000$-2,093,000
    EBITDA$-5,012,000$-7,297,000$-6,511,000$-5,016,000$-4,707,000$-3,687,000$-2,683,000$-2,470,000$-1,785,000$-3,617,000$-4,110,000$-1,944,000
    EBIT$-5,523,000$-7,751,000$-6,953,000$-5,400,000$-5,013,000$-3,864,000$-2,827,000$-2,616,000$-1,930,000$-3,763,000$-4,259,000$-2,093,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VVOS

    News

    Vivos Therapeutics to acquire minority stake in SOD Sciences in $12M stock transaction

    Vivos Therapeutics has agreed to acquire an 11% fully diluted equity stake in SOD Sciences and a 50% co-ownership in its pseudohypoxia early-warning test through a $12 million stock transaction. The deal...

    TradingView•10/15/26•Somewhat-Bullish

    Vivos Therapeutics to Exchange $12M Series C Preferred for 11% of SOD and 50% Test IP

    Vivos Therapeutics announced a strategic stock-for-assets transaction with SOD Sciences. Vivos will exchange $12 million in Series C Convertible Preferred Stock for approximately 11% of SOD Sciences and a 50%...

    TradingView•10/15/26•Somewhat-Bullish

    Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

    Vivos Therapeutics has entered into an agreement to acquire an 11% equity interest in SOD Sciences and a 50% co-ownership interest in SOD's proprietary pseudohypoxia early-warning test. This transaction...

    Yahoo Finance Singapore•10/15/26•Bullish

    Vivos Therapeutics to Acquire 11% Stake in SOD Sciences in $12M Stock Deal

    Vivos Therapeutics (Nasdaq: VVOS) is acquiring an 11% equity stake in SOD Sciences and a 50% ownership in its pseudohypoxia testing technology for $12 million in preferred stock. This strategic move aims to expand Vivos'...

    citybiz•10/15/26•Somewhat-Bullish

    Vivos Therapeutics Inc (VVOS-Q) Stock Price and News

    This article provides stock price and news updates for Vivos Therapeutics Inc (VVOS-Q), a medical technology company focused on sleep-disordered breathing solutions. It includes real-time stock data...

    The Globe and Mail•10/14/26•Neutral

    VVOS Valuation and Fair Value

    P/E
    -0.1x
    P/FCF
    -0.1x
    P/B
    -0.6x
    See GNG's fair value

    VVOS Profitability: Margins, ROIC and FCF

    Gross margin
    61.9%
    Operating margin
    -93.6%
    Net margin
    -121.8%
    ROIC
    -459.5%
    ROE
    -8585.0%
    FCF margin
    -116.6%
    FCF yield
    -1028.3%

    VVOS Competitors

    CompanyTicker
    bioAffinity Technologies, Inc.BIAF
    Enlivex Therapeutics LtdENLV
    Redhill Biopharma LtdRDHL
    NuCana PLCNCNA
    XTL Biopharmaceuticals Ltd ADRXTLB
    Dermata Therapeutics IncDRMA
    Intelligent Bio Solutions Inc.INBS
    Liminatus Pharma, Inc. Class A Common StockLIMN

    Sector: Healthcare

    VVOS Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VVOS Bull Case vs Bear Case

    Bull case

    • VVOS grew quarterly revenue 34.9% year over year.

    Bear case

    • VVOS has a -121.8% net profit margin.

    VVOS Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    3.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.30
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About VVOS

    Does VVOS pay dividends?

    Vivos Therapeutics Inc (VVOS) does not currently pay a regular dividend.

    What is VVOS's market cap?

    Vivos Therapeutics Inc (VVOS) has a market capitalization of $4.50M with a current stock price of $0.13.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In